Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell growth-regulating nucleolar protein Ly1 antibody reactive (LYAR)
- Target
- LYAR
- Molecular classification
- Zinc finger protein, Transcription factor, Nucleolar protein
01
Overview
Cell growth-regulating nucleolar protein Ly1 antibody reactive (LYAR) is a zinc finger nucleolar protein that functions as a transcription factor with DNA-binding activity. It regulates genes involved in cell proliferation, ribosome biogenesis, erythrocyte development, and immune response. LYAR is highly expressed in embryonic stem cells, where it sustains cell self-renewal and controls differentiation via nucleolin stabilization and rRNA processing. In cancer, LYAR is frequently overexpressed, promoting tumor progression, metastasis, and poor clinical outcomes by enhancing cell migration, invasion, and suppressing oxidative stress response genes. LYAR also negatively regulates the innate antiviral response and pro-inflammatory cytokine transcription by interfering with IRF3 and NF-κB activity. Its clinical relevance as a prognostic biomarker is supported across several tumor types, but no pharmacological agents currently target LYAR directly.
- Other names
- Ly1 antibody reactiveLYARCell growth-regulating nucleolar proteinPNAS-5ZC2HC2ZLYARLy1 antibody reactive homolog
02
Mechanism of action
Not applicable; mechanism for hypothetical targeting would be transcription regulation inhibition, cell proliferation suppression, or modulation of innate immune response
03
Biological functions
Cell growth regulationEmbryonic stem cell self-renewal and differentiationRibosome biogenesis and rRNA processingNegative regulation of innate immune responseTranscriptional repression (e.g., gamma-globin, oxidative stress genes)Regulation of erythrocyte development
04
Disease associations
Cancer (neuroblastoma, hepatocellular carcinoma, colorectal cancer, pan-cancer; high expression correlates with poor prognosis, advanced grade, and metastatic potential)Hematologic disorders (association with fetal hemoglobin in β-thalassemia)Neural tube defects (developmental role)Other (potential roles in reproductive cell maturation, e.g., spermatogenesis in mice)Ovarian cancer (prognostic value)Retinal disease (possible involvement via phagocytosis regulation)
05
Safety considerations
No known drug-related safety concerns, as LYAR is not an approved drug target.Potential risks if targeted: disruption of ribosome biogenesis, impairment of stem cell maintenance, dysregulation of hematopoiesis, or immune suppression
06
Biomarkers
High LYAR expression as a negative prognostic biomarker in cancer (pan-cancer analysis, neuroblastoma, hepatocellular carcinoma, colorectal cancer, ovarian cancer)Associated genes for prognosis: MKI67IP, BZW2, CCT2 (correlated in hepatocellular carcinoma as biomarkers)
Beyond the preview
Go deeper on Cell growth-regulating nucleolar protein Ly1 antibody reactive (LYAR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cell growth-regulating nucleolar protein Ly1 antibody reactive (LYAR).